Gardasil Dosing Recommendations
Gardasil 9 is administered as 0.5 mL intramuscularly in the deltoid or anterolateral thigh, with a 2-dose schedule (0,6-12 months) for ages 9-14 years, or a 3-dose schedule (0,2,6 months) for ages 15-45 years. 1
Age-Based Dosing Algorithm
Ages 9-14 Years
- Preferred regimen: 2-dose schedule
- Dose 1: Day 0
- Dose 2: 6-12 months after first dose
- Critical timing: If the second dose is given earlier than 5 months after the first dose, administer a third dose at least 4 months after the second dose 1
- Alternative: 3-dose schedule (0,2,6 months) is also acceptable 2, 3
The 2-dose schedule for this age group is supported by robust immunogenicity data showing non-inferior antibody responses compared to the 3-dose schedule in older individuals 4, 5. This simplified regimen improves vaccine uptake and program efficiency while maintaining protection 6.
Ages 15-45 Years
- Required regimen: 3-dose schedule only
- Dose 1: Day 0
- Dose 2: 2 months after first dose
- Dose 3: 6 months after first dose 1
Minimum Dosing Intervals (When Needed)
If doses are administered off-schedule:
- Minimum interval between doses 1 and 2: 4 weeks
- Minimum interval between doses 2 and 3: 12 weeks 2
- Doses given at shorter intervals than recommended should be readministered 2
Administration Details
Route and site: Intramuscular injection in the deltoid muscle (preferred) or anterolateral thigh 2, 1
Dose volume: 0.5 mL per dose 2, 1
Preparation: Shake vial or syringe well immediately before use; vaccine should appear as a white cloudy liquid 1
Post-administration observation: Observe patients for 15 minutes due to syncope risk, which can occur with tonic-clonic movements 1
Interrupted Schedules
The series does not need to be restarted if interrupted 2. Management depends on which dose was delayed:
- If interrupted after dose 1: Give dose 2 as soon as possible, then ensure doses 2 and 3 are separated by at least 12 weeks
- If only dose 3 is delayed: Administer as soon as possible 2
Special Populations
Routine Vaccination Recommendations
- Primary target: Ages 11-12 years (can start as early as age 9) 2, 3, 2
- Catch-up vaccination: Ages 13-26 years for those not previously vaccinated or who haven't completed the series 2, 3, 7
- Shared clinical decision-making: Ages 27-45 years—vaccination may benefit some adults at risk for new HPV infection, though population benefit is minimal due to prior exposure 7
Immunocompromised Individuals
Use the 3-dose schedule regardless of age at initiation 7, 4
Pregnancy
Not recommended during pregnancy. If pregnancy occurs during the series, postpone remaining doses until after delivery 3. No pregnancy test is required before vaccination 3.
Prior Sexual Activity
Vaccinate regardless of sexual history. While vaccine efficacy is highest before HPV exposure, most sexually active individuals have not been infected with all vaccine types and will derive benefit 2. No HPV DNA or antibody testing is needed before vaccination 2.
Co-administration
Gardasil 9 can be administered simultaneously with other age-appropriate vaccines (Tdap, meningococcal conjugate, hepatitis B) using separate syringes at different anatomic sites 2
Critical Caveats
- Not licensed for use in individuals <9 years or >45 years 2
- Contraindicated in those with hypersensitivity to yeast or any vaccine component 3, 1
- Does not eliminate need for cervical cancer screening—the vaccine covers only 70% of cervical cancer-causing HPV types 2
- Not a treatment for existing HPV infection or disease 1
The evidence strongly supports the 2-dose schedule for younger adolescents as equally protective and more practical than the traditional 3-dose regimen, representing a significant advancement in HPV vaccination programs globally 4, 5, 8.